IMMUNOAGONIST CONVERTS CMV-SPECIFIC T CELLS INTO MORE POTENT HIV-SPECIFIC CAR-T CELLS
We developed novel immunoagonists (synTacs) to selectively activate and expand virus-specific CD8+ T cells in vitro and in vivo. SynTacs consist of dimeric Fc-domain scaffolds linking CD28-specific agonists to HLA-A2 MHC molecules covalently-tethered to a virus-derived peptide enabling delivery of TCR-specific and costimulatory signals to antigen-specific T cells. We hypothesized that synTac-activation of virus-specific effector-memory…